1,602,192 Shares of Danaher Corporation $DHR Bought by Winslow Capital Management LLC

Danaher logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Winslow Capital Management acquired 1,602,192 Danaher shares in the third quarter, worth about $355 million and representing 0.23% of the company.
  • Danaher reported quarterly EPS of $2.11, beating the $1.92 consensus estimate, while revenue of $6.55 billion was slightly below expectations; revenue grew 8.3% year over year.
  • Analysts have a consensus “Moderate Buy” rating and an average price target of $242.91; 18 analysts rate the stock Buy and five rate it Hold.
  • Five stocks we like better than Danaher.

Winslow Capital Management LLC acquired a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,602,192 shares of the conglomerate's stock, valued at approximately $354,966,000. Danaher accounts for about 1.3% of Winslow Capital Management LLC's holdings, making the stock its 27th biggest holding. Winslow Capital Management LLC owned 0.23% of Danaher as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in Danaher in the second quarter valued at $10,492,520,000. Wellington Management Group LLP boosted its holdings in shares of Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate's stock worth $3,108,031,000 after buying an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new position in Danaher during the second quarter worth $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the 2nd quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE acquired a new stake in Danaher in the second quarter valued at approximately $993,846,000. Institutional investors own 79.05% of the company's stock.

Danaher Price Performance

NYSE DHR opened at $220.42 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.29 and a current ratio of 1.63. The stock has a 50-day moving average of $224.82 and a 200 day moving average of $201.66. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a market capitalization of $155.07 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 2.77 and a beta of 0.76.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion for the quarter, compared to analysts' expectations of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The business's revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the firm posted $1.89 earnings per share. On average, sell-side analysts forecast that Danaher Corporation will post 8.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a $0.40 dividend. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher's payout ratio is currently 26.19%.

Analysts Set New Price Targets

Several research firms have commented on DHR. DZ Bank lowered shares of Danaher from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 27th. Citigroup upped their price objective on shares of Danaher from $230.00 to $270.00 and gave the company a "buy" rating in a report on Thursday, October 22nd. JPMorgan Chase & Co. raised their price target on Danaher from $250.00 to $270.00 and gave the stock an "overweight" rating in a report on Thursday, October 22nd. Royal Bank Of Canada lifted their price objective on Danaher from $215.00 to $250.00 and gave the company an "outperform" rating in a research note on Monday, October 5th. Finally, Guggenheim increased their target price on Danaher from $200.00 to $250.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $242.91.

View Our Latest Analysis on Danaher

Insiders Place Their Bets

In other Danaher news, EVP Gregory Milosevich sold 2,100 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $230.62, for a total transaction of $484,302.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $5,158,277.54. This trade represents a 8.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Christopher Bouda sold 7,598 shares of the business's stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total value of $1,782,186.88. Following the sale, the chief accounting officer directly owned 9,107 shares in the company, valued at $2,136,137.92. The trade was a 45.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 10.80% of the stock is currently owned by corporate insiders.

About Danaher

(Free Report)

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company's businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines